Pfizer Kansas plant hit by FDA 483 with 8 repeat observations - bioprocessintl.com
Pfizer Kansas plant received an FDA 483 with 8 repeat observations, indicating ongoing compliance issues with cGMP standards.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on September 2, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. All pharmaceutical manufacturers, especially those involved in production and compliance oversight. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediate attention required; no specific deadline stated.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
The FDA issued a Form 483 citing repeat observations of non-compliance with good manufacturing practices.
Who it affects
All pharmaceutical manufacturers, especially those involved in production and compliance oversight.
What you must do
Review and address the compliance issues identified in the FDA 483 to avoid further regulatory action.
Deadline
Immediate attention required; no specific deadline stated.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- The Impact of Reclassifying 7-OH Products - pharmtech.com
- Issuance of Priority Review Voucher; Rare Pediatric Disease Product; GENGLYCOS (parisglasgene brecaparvovec-opnr)
- Determination That CARAFATE (Sucralfate) Oral Suspension, 1 Gram/10 Milliliters, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- UW Carbone Cancer Center receives FDA clearance to test new regenerative medicine therapy for radiotherapy-induced dry mouth - med.wisc.edu
- GLP-1 Drugs: Ohio Board of Pharmacy Issues FAQs for Compounders - natlawreview.com